Seralutinib is under clinical development by Gossamer Bio and currently in Phase III for Pulmonary Arterial Hypertension. According to GlobalData, Phase III drugs for Pulmonary Arterial Hypertension have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Seralutinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seralutinib overview
Seralutinib is under development for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug candidate is administered as an inhalation in the form of powder and orally as a capsule. It acts by targeting CSF1R, c-KIT, PDGF subtype A and B.
Gossamer Bio overview
Gossamer Bio (Gossamer) is a clinical-stage biopharmaceutical company. It develops and commercializes seralutinib (GB002) inhaled platelet-derived growth factor receptor (PDGFR), CSF1R, c-KIT inhibitor that targets pulmonary arterial hypertension (PHA). The company works with biotechnology pharmaceutical companies and academic centers, among others. It operates through GB002 Inc and Gossamer Bio Services Inc subsidiaries in Delaware. Gossamer is headquartered in San Diego, California, the US.
For a complete picture of Seralutinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
